M. Michele Manos, PhD, MPH, DVM

M. Michele Manos, PhD, MPH, DVM Kaiser Permanente Division of Research
2000 Broadway
Oakland, CA 94612

(510) 891-3400 (phone)
michele.manos@kp.org

M. Michele Manos, PhD, MPH, DVM, is a senior research scientist at the Kaiser Permanente Northern California Division of Research; an adjunct professor at Johns Hopkins University; and a veterinarian. Dr. Manos serves as the director of the Kaiser Permanente Viral Hepatitis Registry. During the past 25 years, she has directed both laboratory science and epidemiological investigations. Dr. Manos’s research areas have included viral hepatitis and other chronic liver diseases, the etiology and prevention of cervical cancer and liver cancer, development of human papillomavirus (HPV) testing technologies, and community-based health assessments in minority populations. She has collaborated on diverse issues ranging from women’s health in Afghanistan to zoonotic diseases in marine mammal workers. As a veterinarian, Dr. Manos is interested in wildlife and livestock population health.

Current Position(s):

Research Scientist III, Division of Research, Kaiser Permanente Northern California
Adjunct Professor, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University

Primary Research Interests:

Epidemiology and management of viral hepatitis B and C
Trends in the incidence and underlying causes of liver cancer
Health policy issues in cancer prevention and control
Racial and ethnic disparities in health care and disease outcomes
Infectious diseases at the interfaces between wildlife, domestic animals, and humans

Characteristics of chronic hepatitis B patients in a managed care setting

Describe the virologic measurements, immunologic status (HBV related), liver disease conditions, demographics and treatment histories of a current cohort of adult members with chronic hepatitis B. In a subset of patients receiving antiviral therapy for 2 years or more, assess liver disease markers, comorbidities and severe outcomes.
Funder: Gilead, Inc.
Principal Investigator: Manos, Michele

Hepatitis C Cooperative Research Centers (U19)

The project will address the immunological and immunogenetic correlates of response to antiviral therapy for HCV. Two distinct but complimentary laboratory projects will study the innate and adaptive responses in blood samples from both a retrospective cohort of patients previously treated, and a prospecitve cohort of patients during the first 12 weeks of therapy.
Funder: Nat. Inst. of Allergy and Infectious Diseases
Principal Investigator: Manos, Michele

Quality and Efficiency of Hepatocellular Carcinoma Reporting to Cancer Registries

This SEER Rapid Response Surveillance Study will investigate hepatoma under-reporting in Kaiser Permanente Northern California and identify key patient characteristics that enable efficient ascertainment of hepatocellular carcinoma cases that are missed by usual cancer surveillance methods.
Funder: National Cancer Institute
Principal Investigator: Manos, Michele

Feasibility and Potential Impact of Birth Cohort-Based Hepatitis C Screening

The goal of this feasibility study is to estimate the potential public health and medical care impact of recommended changes in CDC guidelines that all "baby boomers" be screened for hepatitis C regardless of risk, and to design a program evaluation in one to three Kaiser Permanente Northern California facilities.
Funder: Centers for Disease Control and Prevention
Principal Investigator: Manos, Michele

Health care utilization and costs associated with antiviral treatment for hepatitis C

The goals of this study, which uses data in the Viral Hepatitis Registry for HCV patients treated 2002-2007, are to assess health care utilization and associated costs for one year prior to, during, and up to 5 years after treatment for those with successful versus unsuccessful treatment; and also to assess the effect of drug exposure duration on the incidence of side-effects (e.g. anemia, depression) and the costs associated with such during treatment courses with PEG-IFN/ribavirin.
Funder: Vertex Pharmaceuticals, Inc.
Principal Investigator: Manos, Michele

A Cross-sectional Study of Hepatitis C Patients in a Managed Care Setting

This descriptive study characterizes the approximately 21,000 hepatitis C patients who were members of the Kaiser Permanente Northern California health plan in December 2008 and were identified by the KP Viral Hepatitis Registry. Demographic, general medical, antiviral treatment, liver disease markers, and liver disease outcomes are being evaluated.
Funder: Merck and Co., Inc.
Principal Investigator: Manos, Michele

Predictors of Severe Outcomes in Hepatitis B Patients

This project, using electronic data maintained in the Viral Hepatitis Registry for patients with chronic hepatitis B, seeks to determine the rates of mortality (all cause and liver disease) and specific liver disease outcomes (decompensated cirrhosis, hepatoma, transplant).
Funder: Gilead, Inc.
Principal Investigator: Manos, Michele

Kaiser Permanente Viral Hepatitis Registry

The Viral Hepatitis Registry work includes identification of, and electronic medical record data collection from, retrospective cohorts of chronic viral hepatitis cases.
Funder: The Permanente Medical Group
Principal Investigator: Manos, Michele

Kaiser Permanente Division of Research